1. Short title This Act may be cited as the Advancing Access to Precision Medicine Act . 2. National Academy of Medicine study (a) In general Not later than 60 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall enter into an arrangement with the National Academy of Medicine under which the Academy agrees to study— (1) how genetic and genomic testing may improve preventative care and precision medicine; (2) how genetic and genomic testing may reduce health disparities; (3) how the Federal Government may help to reduce barriers to genetic and genomic testing, including— (A) encouraging the expansion of health insurance coverage of genetic and genomic testing, including diagnostic, predictive, and presymptomatic testing, and whole genome sequencing; (B) supporting the collection of evidence for the clinical utility and appropriate use of genetic and genomic tests; and (C) improving access to genetic counselors, pathologists, and other relevant professions, including strengthening related workforce education and training efforts; (4) (A) the extent to which coverage provisions in the Medicare and Medicaid programs under titles XVIII and XIX of the Social Security Act ( 42 U.S.C. 1395 et seq., 1396 et seq.) may restrain the use of genetic and genomic testing that may improve clinical outcomes for beneficiaries; and (B) how the Centers for Medicare & Medicaid Services may make coverage determinations that better suit a precision medicine approach to treatment; and (5) how genetic and genomic testing may improve health outcomes for all populations in the United States, including— (A) individuals with a rare disease, including— (i) a metabolic disease; (ii) a hereditary cancer syndrome; and (iii) a neurologic disease with known treatments; and (B) special populations, including— (i) infants and children; (ii) critically ill (non-infectious and non-trauma) patients; (iii) transplant patients; (iv) individuals with cardiac disease